Revance Therapeutic (RVNC) PT Lowered to $25 at Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St futures gain on tech rebound, Middle East peace hopes
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil falls 1% as traders digest escalation in US-Iran strikes
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- UBS sees generational semiconductor boom, highlights stock winners
Revance Therapeutic (RVNC) PT Lowered to $26 at Mizuho Securities
October 18, 2021 6:34 AM EDTMizuho Securities analyst Difei Yang lowered the price target on Revance Therapeutic (NASDAQ: RVNC) to $26.00 (from $36.00) while maintaining a Buy rating.... More
Revance Therapeutic (RVNC) PT Lowered to $18 at H.C. Wainwright
October 18, 2021 6:33 AM EDTH.C. Wainwright analyst Douglas Tsao lowered the price target on Revance Therapeutic (NASDAQ: RVNC) to $18.00 (from $26.00) while maintaining a Buy rating.... More
Revance Therapeutics (RVNC) Announces FDA is Unable to Approve DaxibotulinumtoxinA; Management Plans to Request Type A Meeting
October 18, 2021 5:17 AM EDT(Updated - October 18, 2021 6:40 AM EDT)
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the United States (U.S.) Food and Drug Administration (FDA) has issued a Complete Response Letter, or CRL, regarding the Biologics... More
